Physician profile
Hailey Armstrong
NPI 1326463175
$12,316.15
in general payments reported to CMS, 2019-2025
49 companies · $3,008 in 2025
The $3,008 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,593 · 2022: $1,274 · 2023: $2,587 · 2024: $2,854 · 2025: $3,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,242 · Consulting Fee: $113 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,241.64 |
| Consulting Fee | $112.84 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,906.22 | 2021-2025 | |
| Novo Nordisk INC | $1,397.47 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $877.63 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $821.90 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $658.27 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $630.34 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $564.15 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $555.55 | 2021-2025 | Repatha, Otezla, Otezla |
| Sumitomo Pharma America, INC. | $486.88 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.57 | 2021-2025 | Synjardy, Tradjenta, Jardiance |
| Merck Sharp & Dohme LLC | $377.69 | 2021-2025 | Belsomra, Verquvo, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $327.13 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $305.76 | 2021-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $260.74 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $254.26 | 2024-2025 | Caplyta |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $249.80 | 2021-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $236.67 | 2021 | |
| Janssen Scientific Affairs, LLC | $169.35 | 2025 | Tremfya |
| Sanofi-Aventis U.S. LLC | $156.04 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $146.59 | 2021-2022 | |
| Axsome Therapeutics, INC. | $145.07 | 2024-2025 | Auvelity |
| Paratek Pharmaceuticals, INC. | $140.58 | 2021-2023 | Nuzyra |
| Exact Sciences Corporation | $132.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $115.79 | 2021-2025 | Nexletol |
| Adma Biomanufacturing LLC | $112.84 | 2023 | |
| Astellas Pharma US INC | $110.45 | 2023-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $99.18 | 2021-2022 | |
| Biogen, INC. | $88.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $81.67 | 2022-2025 | |
| Janssen Biotech, INC. | $53.49 | 2025 | Tremfya |
| Scilex Pharmaceuticals INC. | $49.05 | 2023-2025 | Ztlido |
| Eisai INC. | $44.56 | 2021-2022 | |
| Antares Pharma, INC. | $33.69 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Philips North America LLC | $29.01 | 2024-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Ck7) Extended Holter |
| Arbor Pharmaceuticals, INC. | $28.04 | 2021 | |
| Daiichi Sankyo INC. | $23.85 | 2022 | |
| Inspire Medical Systems, INC. | $20.75 | 2024 | Inspire |
| Abbott Laboratories | $20.61 | 2024 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $20.28 | 2021 | |
| Shield Therapeutics INC | $20.19 | 2023 | Accrufer |
| Ardelyx, INC. | $17.59 | 2024 | Ibsrela |
| Sanofi Pasteur INC. | $17.38 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $17.15 | 2025 | Rexulti |
| Averitas Pharma INC. | $17.00 | 2024 | Qutenza |
| Seqirus USA INC | $15.81 | 2024 | Fluad, Flucelvax |
| Axonics, INC. | $14.88 | 2023 | Axonics |
| Biohaven Pharmaceuticals, INC. | $14.09 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.79 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailey Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.